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Abstract 
Stroke is a debilitating disease that currently affects 50000 people in Canada yearly. 
Understanding the responses of the brain to a small clinically relevant model of ischemic 
stroke can lead to new and improved therapies to help improve stroke recovery. This 
thesis has characterized the endogenous responses to an Endothelin-1 (ET-1) mediated 
small focal ischemic injury over the first 10 days post-stroke. Major findings include the 
discovery and characterization of the spread of astrocyte activation across the cortex 
including activation in the contralateral cortex. Studies into the proliferative response of 
neural precursor cells showed a significant increase in the newborn neuroblast 
population.These results can lead to a greater understanding of the role of glial cells post-
stroke and to the identification of an optimal time window in which to promote NPC 
survival post-stroke and improve stroke recovery. 
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1 Introduction 
1.1 Current state of stroke care and stroke recovery 
Stroke is a far reaching disease, as part of vascular disease it is the most severely 
debilitating illness in the world. Vascular disease comprises 50,000 strokes in Canada 
annually (Adamson, Beswick, & Ebrahim, 2004; Hodgson, 1998). The majority of 
strokes are not fatal but disabling, with over 59% of people surviving the first year post-
stroke (Bronnum-Hansen, Davidsen, & Thorvaldsen, 2001). Although many people 
survive their first stroke, the risk for subsequent strokes is high and there is a high rate of 
mortality within the first five years post-stroke (Bronnum-Hansen et al., 2001; Ng, Stein, 
Ning, & Black-Schaffer, 2007).  Therefore, chronic care and recovery from stroke must 
be a key goal in alleviating the burden of vascular disease and the risk of subsequent 
strokes. 
There are two types of stroke: ischemic and hemorrhagic. Ischemic stroke is responsible 
for 85% of all strokes and is defined as a lack of perfusion of blood to the brain (Smith, 
2011). Hemorrhagic stroke is defined by the breakage of a blood vessel in the brain 
leading to intracranial bleeding, forming a hematoma. Patients who have an ischemic 
stroke have a better prognosis than those who suffer a hemorrhagic stroke (Andersen, 
Olsen, Dehlendorff, & Kammersgaard, 2009). This can be observed by comparing the 30-
day mortality of ischemic stroke which is 12.7% compared to the 39.3% mortality for 
hemorrhagic stroke patients (Fang, Perraillon, Ghosh, Cutler, & Rosen, 2014). This thesis 
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focuses on ischemic stroke because of its higher prevalence and relatively higher 
survivability compared to hemorrhagic stroke. 
The current state of stroke care is focused on reperfusion of the ischemic brain, followed 
by physical rehabilitation to aid functional recovery through the remapping of interrupted 
or lost motor pathways (Adkins-Muir & Jones, 2003; Fonarow et al., 2014; Kwakkel, 
2006). Acute stroke care is focused on breaking the clot and establishing reperfusion to 
the injured area of the brain. To aid in breaking up the clot there is one drug treatment 
that can be applied acutely: tissue plasminogen activator (t-PA) (Banerjee, Williamson, 
Habib, & Chataway, 2012; Fisher et al., 2009). The major limitation of t-PA is that it 
must be given within a strict 4.5 hour time window post-stroke to have a positive effect 
on the patient’s outcome (Del Zoppo, Saver, Jauch, & Adams, 2009; Hinkle & Guanci, 
2007; Picanço et al., 2014). Unfortunately, many patients arrive to the hospital after this 
4.5 hour window and have few treatment options available (Barber, Zhang, Demchuk, 
Hill, & Buchan, 2001). To address this need, over 100 clinical trials have been conducted 
to test novel neuroprotective therapies to improve post-stroke recovery. None have 
proven to be successful (Gladstone, Black, & Hakim, 2002). Improvement in novel 
neuroprotective therapies for stroke recovery is needed because of the high survival rate 
of patients with stroke and the risk of recurrent strokes (Roger et al., 2011; Zeiler et al., 
2013). To improve post-stroke recovery, a new method must be exploited to lead to truly 
translational and successful therapies. 
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1.2 Pathology of ischemic stroke 
Stroke is a disease with many different facets and a wide variability of outcomes. 
However, stroke follows a well-defined pathology (Brouns & De Deyn, 2009; Garcia et 
al., 1993). Ischemic stroke may begin as a quick event with the formation of a blood clot 
in the brain but the long term progression that follows, including paralysis and memory 
deficits continues for life (Garcia et al., 1993). While the physiological and functional 
responses to ischemic stroke have been studied, there is still a lack of understanding of 
the cellular response including the neural precursor response, and the glial response to a 
small focal ischemic injury (Deb, Sharma, & Hassan, 2010; Dereski, Chopp, Knight, 
Rodolosi, & Garcia, 1993; Hall, Davies, Stamp, Clamp, & Bigley, 2013; Neher et al., 
2013). In addition, co-morbidities such as dementia, diabetes, atrial fibrillation and 
coronary artery disease have an impact on stroke and outcomes post stroke (Fischer et al., 
2006). Ischemic injuries are variable depending on the size, location and the collaterals in 
the brain, but many injuries have similar pathology and common pathways. 
Ischemic stroke has a large number of causes ranging from small vessel disease to large 
artery occlusion. A large proportion of strokes arise from clots within the branches of the 
middle cerebral artery (MCA) (Carmichael, 2005). Occlusion of these blood vessels 
restricts the nutrients available to the surrounding tissue. This lack of oxygen and glucose 
to the brain rapidly causes cell death (Deb et al., 2010). There is a combination of both 
necrotic and apoptotic cell death post-stroke (Hall et al., 2013). Cell death within the core 
of the infarct is primarily necrotic because the dying cells do not have the required energy 
to activate the apoptotic cascade (Deb et al., 2010). Cell death causes cells to burst and 
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release intracellular contents into the extracellular space. These contents include 
glutamate and reactive oxygen species (ROS)  that are toxic and cause apoptosis to the 
surrounding cells (Deb et al., 2010). Secondary cell death surrounding the infarct 
transitions into a mixture of apoptotic and necrotic cell death over the following days 
post-stroke. 
The area surrounding the infarcted core is an area of tissue known as the penumbra that, 
while hypo-perfused, can contain viable tissue (Astrup, Siesjo, & Symon, 1981; Baron, 
Yamauchi, Fujioka, & Endres, 2014; Deb et al., 2010). This area is a well-known 
hallmark of stroke pathology (Garcia et al., 1993). Although the penumbra is at risk of 
further cell loss, the viable tissue there has the potential to be saved if action is taken 
quickly to resolve the stroke (Albers et al., 2006; Baron et al., 2014). The penumbra is a 
crucial area post-stroke that if saved can drastically change the outcome of post-stroke 
recovery. 
A major part of the post-stroke response from glial cells is to create a barrier that 
separates the healthy and injured tissue. This barrier, often seen years post-stroke in 
human patients, is called the glial scar (Rolls, Shechter, & Schwartz, 2009). The scar is 
composed primarily of activated astrocytes as well as some immune cells, together they 
form a physical barrier surrounding the ischemic core (Huang et al., 2014; Stoll, 1998; 
Yuan & He, 2013). The formation of the glial scar separates the ischemic core from the 
healthy brain, and is seen in all ischemic injuries (Stichel & Müller, 1998). The glial scar 
prevents excitotoxicity and further apoptosis of cells in the cortex, by limiting the spread 
of glutamate and ROS within the ischemic core (Brouns & De Deyn, 2009). The 
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formation of the glial scar is a robust response that occurs within the first hours to days 
post-stroke (Rolls et al., 2009). The formation of the glial scar plays an important aspect 
in post-stroke pathology, by defining the size of the infarct. 
The vasculature in the post-ischemic brain is seen as one area where intervention can 
improve stroke recovery. Vascular disease can increase the breakdown of the blood brain 
barrier (BBB), resulting in immune cells infiltrating the ischemic region (Bush et al., 
1999; Stoll, 1998; Tennant & Brown, 2013). Unfortunately, these cells not only clear the 
dead and dying cells within the core, but also destroy some of the viable brain tissue 
surrounding the core (Neher et al., 2013). The vascular response to stroke is of the utmost 
importance to aiding in stroke recovery (Schellinger et al., 2013). The vascular response 
is comprised of the reperfusion, which provides oxygen and glucose to the injured area 
but also the creation of new blood vessels.  The vasculature delivers nutrients once 
reperfusion is established and is used as a scaffold for neuroblasts post-stroke (Brouns & 
De Deyn, 2009; Kahle & Bix, 2013; Thored et al., 2006). This is reinforced by the fact 
that a lack of viable blood vessels limits neuroblast migration to the site of injury in the 
post-ischemic cortex (Kahle & Bix, 2013). Blood vessels act as both a structural support 
and a nutrient delivery system to the brain. Breakdown of blood vessels leads to cell 
death due to a lack of nutrition and oxygen to the surviving tissue. 
Ischemic stroke is a diverse disease with many players. Firstly, there is necrotic cell death 
associated with a lack of blood flow to the ischemic region. This is followed by an 
increase in apoptotic cell death and a glial cell response, as the intracellular components 
of necrotic cells from the ischemic core are released. With the breakdown of blood 
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vessels within the ischemic region, the brain also loses a method in which to transport 
oxygen and nutrition to surviving cells and a structural support. Together these responses 
interact and form the pathology of an ischemic injury. 
1.3 The pro-survival and regenerative responses to ischemic stroke 
While there is an increase in cell death and glial cell activation as part of the endogenous 
response to ischemia, there is also a pro-survival response. This can be seen by the 
specific increase in pro-survival and growth factors in the post-ischemic cortex, such as 
brain-derived neurotrophic factor (BDNF) which has been implicated in improved 
recovery and angiogenesis (Lopez-Lopez, LeRoith, & Torres-Aleman, 2004; Ploughman 
et al., 2007). Taking advantage of the endogenous pro-survival response allows for new 
treatments to improve stroke recovery. 
 To improve stroke recovery, a window for introduction of novel therapies has been 
suggested.  A window of 5 to 14 days post-stroke has been suggested to yield optimal 
recovery (Krakauer, Carmichael, Corbett, & Wittenberg, 2012; MacLellan et al., 2011; 
Murphy & Corbett, 2009). A number of studies have focused on identifying the optimum 
time point following stroke to begin physical rehabilitation in order to maximize 
functional recovery. Studies that started physical rehabilitation between 5 to 14 days post-
stroke found animals had improved functional recovery.  Functional recovery was not 
observed when physical rehabilitation was started at 30 days (Biernaskie, Chernenko, & 
Corbett, 2004). This is reinforced through clinical studies where earlier rehabilitation 
resulted in better functional outcomes in humans (Horn et al., 2005). One of the potential 
reasons why early intervention leads to improved functional outcomes is that higher 
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levels of growth factors are present at the early time points. Growth factors that have 
been implicated in axonal sprouting, such as GAP 43, CAP 23 and c-JUN are upregulated 
by 3 days post-stroke and remain elevated until 28 days post-stroke (Carmichael et al., 
2005). This is followed by the upregulation of axonal growth inhibitors, such as 
Aggrecan, and NG2. The majority of these inhibitory genes have peak levels of gene 
expression from 14 to 28 days post-stroke (Carmichael et al., 2005). This period, when 
growth factors are at high levels and before growth inhibitors are upregulated has been 
termed a critical period to improve stroke recovery (MacLellan et al., 2011). A potential 
time window for optimal rehabilitation can be found by overlapping the periods of 
effective rehabilitation with the upregulation of survival genes but excluding the period 
of increased inhibitory genes (Fig. 1.1). This period was defined to help improve 
rehabilitation and increase remapping of motor-maps (Harrison & Murphy, 2012). 
Molecular approaches can help improve rehabilitation since the basis for the period is 
defined by the changes of growth and inhibitory molecular markers (Murphy & Corbett, 
2009). Therefore, it appears that a larger pro-survival and growth factor response during 
the critical period  is necessary to have a meaningful impact on stroke recovery (Osman, 
Porritt, Nilsson, & Kuhn, 2011; Parent, Vexler, Gong, Derugin, & Ferriero, 2002). 
Unfortunately, there is not a large endogenous neurogenic response post-stroke. 
Identification of novel targets that have significant impact on the post-ischemic cortex 
and enhance the endogenous neurogenic response can become an effective treatment 
alone or used in parallel with other treatments to create a synergistic effect. 
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Figure 1.1: Identification of an optimal time window to introduce therapy post-
stroke. 
Timeline showing time windows of growth genes (red) and inhibitory genes (blue) as 
well as the optimal time window to start physical rehabilitation post-stroke (green) 
(Carmichael et al., 2005; Harrison & Murphy, 2012). 
  
5d 14d
9
Inhibitory Factors
Growth Factors
Days post-stroke
0d
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In response to an ischemic injury, the post-ischemic cortex forms a glial scar that limits 
the size of injury. In addition to a glial scar that controls the spread of the size of injury, 
there is a pro-survival response within the post-ischemic cortex. The pro-survival 
response consists of containing the damage and attempting to maintain the survival of 
neurons in the peri-infarct area. How the pro-survival response promotes stroke recovery 
has been well studied (Christie & Turnley, 2012; MacLellan et al., 2011). BDNF is an 
example of a growth factor that increases in the post-ischemic cortex. BDNF is a 
neurotrophic factor that improves functional recovery, and if BDNF is knocked down 
then functional recovery is delayed. BDNF has a critical threshold for its maximal pro-
survival effect post-ischemic injury (MacLellan et al., 2011). To improve functional 
recovery, studies have used multiple therapies to assess if there is synergy between 
treatments. The use of multiple treatments, such as BDNF treatment and enriched 
physical rehabilitation appears to have a synergistic effect, leading to the term “enhanced 
rehabilitation” (Hicks, MacLellan, Chernenko, & Corbett, 2008). Further examples of 
growth factors can be found in Table 1.1. 
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Table 1.1 Response of growth factors post stroke 
Factor Expression post-
stroke 
Effect on NPCs References 
Epidermal growth 
factor (EGF) 
Upregulated Increases proliferation 
and migration of 
NPCs within the SVZ 
(Teramoto, Qiu, 
Plumier, & 
Moskowitz, 
2003) 
BDNF Highly upregulated Differentiation and 
survival of NPCs 
within the SVZ 
(Im et al., 2010) 
Nerve growth factor 
(NGF) 
Upregulated Improves survival  of 
NPCs within the SGZ 
(Zhu et al., 2011) 
Fibroblast growth 
factor 2 (FGF2) 
Upregulated Increases proliferation 
of NPCs within the 
SVZ 
(Türeyen, 
Vemuganti, 
Bowen, Sailor, & 
Dempsey, 2005) 
Glial cell line-derived 
neurotrophic factor 
(GDNF) 
Upregulated Increases proliferation 
of NPCs within the 
SVZ 
(Arvidsson, 
Kokaia, 
Airaksinen, 
Saarma, & 
Lindvall, 2001; 
Kobayashi et al., 
2006) 
Insulin-like growth 
factor 1 (IGF-1) 
Stable Induce migration of 
NPCs within the SVZ 
(Aberg, Aberg, 
Hedbäcker, 
Oscarsson, & 
Eriksson, 2000) 
Pituitary adenylate 
cyclase-activating 
polypeptide (PACAP) 
Upregulated Survival of neurons 
and maintenance of 
the NPC population 
(Chen et al., 
2006; Ohta, 
Gregg, & Weiss, 
2006) 
Vascular endothelial 
growth factor (VEGF) 
Stable Proliferation and 
migration within the 
SVZ 
(Wittko et al., 
2009) 
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Unfortunately, out of all these factors only EGF, which maintains the proliferation of the 
NPC pool, and FGF2 which increases neurogenesis in the rostral migratory stream 
regulate NPCs in vivo (Christie & Turnley, 2012; Kuhn, Winkler, Kempermann, Thal, & 
Gage, 1997). However, these two factors have not been shown to improve stroke 
recovery in a clinical setting. While there are a number of pro-survival factors identified 
and tested, none have had a significant improvement on stroke recovery. To improve 
recovery, identification of an optimal time period of NPC activity post-stroke could 
provide a new time point where these pro-survival factors could have their greatest 
impact.  
 The pro-survival response to an ischemic injury has generated hope that the exogenous 
application of growth and pro-survival factors can lead to improved stroke recovery. 
Therefore, the development of an optimal time window where physical rehabilitation and 
molecular approaches have the greatest effect is crucial to maximize the potential impact 
of novel therapies post-stroke. Understanding the endogenous survival response allows 
for novel therapeutic targets to be identified and studied in greater detail. This can 
ultimately lead to the development of new therapies and improve stroke care. 
1.4 Glial response to ischemic stroke 
Most research focuses on the responses of the neuronal population to an ischemic injury. 
However, to provide a full picture of an ischemic injury, the glial population must also be 
investigated since it plays a role in injury. This allows researchers to understand how 
potential therapeutics will be affected by the astrocyte and microglial cell population (L. 
Huang et al., 2014; Stoll, 1998). The glial response to injury is robust and seen in all 
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central nervous system (CNS) injuries (L. Huang et al., 2014; Rolls et al., 2009; Stichel & 
Müller, 1998; Yuan & He, 2013). The major response of astrocytes and microglia after an 
ischemic injury is to form a physical barrier surrounding the injury to sequester the injury 
from spreading (L. Huang et al., 2014; Stoll, 1998; Yuan & He, 2013). The formation of 
this scar has a large effect on recovery, as it contains the dead and dying cells within the 
ischemic core to prevent the spread of ROS (Yuan & He, 2013). Furthermore, when the 
glial scar is prevented from forming there is a significant decrease in stroke recovery 
(Sofroniew, 2009). However, the glial scar could also become a barrier to neural repair in 
the brain and force remapping of connections to the surviving cortex (Benowitz & 
Carmichael, 2010). Therefore, the time of glial scar formation and characterization of the 
immune cell response may identify good targets for improving stroke recovery. 
1.4.1 Astrocytes 
Astrocytes are found in all parts of the brain and act to provide nutrition as well as 
support to neurons. Astrocytes are the main glial cell type found in the brain comprising 
40-50% of all glial cells (Aldskogius & Kozlova, 1998). Following injury astrocytes 
become activated and become part of the response to the injury. Specifically, astrocytes 
will respond to the injury by upregulating glial fibrillary acidic protein (GFAP), a 
filamentous protein that is expressed in astrocytes and ependymal cells of the CNS. This 
thesis has taken advantage of this by examining the activation of astrocytes, which have 
increased numbers of processes and swollen processes along with increased GFAP 
staining (Aldskogius & Kozlova, 1998). The response of astrocytes to an ischemic stroke 
is highly regulated and follows a distinct pathological progression from the upregulation 
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of GFAP, changes in morphology and leading to their incorporation in the glial scar 
(Stichel & Müller, 1998; Stoll, 1998). In addition to the glial scar there are other effects 
of ischemic stroke on the glial population.  
Following stroke, astrocytes proliferate creating more activated astrocytes within the 
injured brain (Walberer et al., 2010). These astrocytes upregulate a host of proteins to 
either communicate with other cells, such as connexins for the formation of gap 
junctions, or to aid in neuronal survival, such as neurotrophic factors and heat shock 
proteins (Hsps) (Aldskogius & Kozlova, 1998; Barreto, White, Xu, Palm, & Giffard, 
2012). The roles of these activated astrocytes includes the uptake of excitotoxic glutamate 
and ROS (Takatsuru et al., 2013). Astrocytes are also able to exert both pro- and anti-
inflammatory effects on the microglial immune response (Min, Yang, Kim, Jou, & Joe, 
2006). Astrocytes are responsible for a large portion of the post-ischemic response, 
ranging from glial scar formation to supporting the surrounding cells. It still remains 
unknown when astrocytes become activated, and where the activation spreads in the 
ischemic cortex following a small focal ischemic injury. This thesis examines when 
GFAP is upregulated and the area of astrocyte activation following a focal ischemic 
injury. 
1.4.2 Immune response 
The immune system responds to changes to the body. This response also extends to 
ischemic injuries in the brain. Increased necrotic cell death and the release of intracellular 
contents activate a large immune response to ischemic injury (Becker, 1998; Benarroch, 
2013).  The immune response is led by microglia and macrophages that, when activated, 
15 
 
will upregulate the cell surface marker CD-68 (Benarroch, 2013). Microglia are the 
resident immune cells in the brain (Burns & Steinberg, 2011). If there is a breakdown in 
the BBB during the ischemic injury, macrophages from the blood stream will also 
respond to the injury (Bush et al., 1999). Activated immune cells can be identified with 
antibodies to the cell surface marker CD-68, however microglia and macrophages, while 
residing in two different parts of the body, are indistinguishable based on this 
immunohistochemical marker (Guillemin & Brew, 2004). Microglia and macrophages are 
able to regulate the clearing of the infarct site through phagocytosis of the dead and dying 
cells (Iadecola & Anrather, 2011). The glial scar forms a barrier separating the activated 
microglia and macrophages from the healthy tissue thereby delimiting the size of the 
injury. 
Immune cells have a positive role within the injury, by clearing cellular debris, however 
immune cells also create a cytotoxic environment by secreting pro-inflammatory factors 
(Price et al., 2006). These pro-inflammatory factors can induce apoptotic cell death in 
neurons within and surrounding the infarct and in NPC migrating to the infarct (Thored et 
al., 2006). This cytotoxic environment is caused by activated immune cells, specifically, 
the M1 polarized macrophages and microglia (Benarroch, 2013). The polarization of 
immune cells as either phagocytic M1 or neurotrophic M2 is critical to understanding the 
role these cells play in the post-ischemic cortex (Taylor & Sansing, 2013). The M1 
phagocytic immune cells are responsible for causing delayed cell death of neurons and 
glial cells surrounding the infarct up to 7 days post-stroke (Neher et al., 2013). Studies 
which depleted immune cells from the brain resulted in less brain atrophy (Neher et al., 
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2013). This shows that immune cells significantly modulate the outcome of the post-
ischemic brain. Knowing when immune cells first become activated, and when they 
switch from an M1 phagocytic state to an M2 neurotrophic state may help in the future to 
modulate the survival of NPC to have the greatest impact on stroke recovery. 
1.4.3 Removing the glial response 
The glial response has a large impact on the post-ischemic cortex. Studies which have 
removed or modified the glial response have improved our knowledge of the role glial 
cells play in the post-ischemic cortex. Many studies have focused on reducing or 
completely removing the glial scar as it was seen as a barrier to the endogenous 
neurogenic response (Sofroniew, 2009; Yuan & He, 2013). The glial scar forms a 
physical barrier that NPCs will migrate towards but are not able to penetrate. Thus a 
smaller or more porous glial scar may allow NPCs to penetrate the injury and help 
regenerate a portion of the lost tissue. One study knocked-out the glial scar-forming 
astrocytes. To mitigate the confounding effects of knocking out all astrocytes, a knock-
out that provided both temporal and type-specific control was generated. This was 
achieved using GFAP-induced expression of herpes simplex virus thymidine kinase 
combined with the anti-viral drug, ganciclovir, which selectively killed the astrocyte 
population. However, when astrocyte numbers were reduced and no glial scar formed, a 
larger ischemic injury was observed compared to control animals (Sabelström et al., 
2013). This evidence shows that astrocytes and the glial scar also have a protective role in 
the injured brain. Therefore, it is critical to learn more about the glial scar, when it forms, 
and how it plays a positive role in mitigating the size of an infarct by limiting expansion 
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of the injury site. Understanding the glial response can lead to new therapeutic targets for 
improving stroke recovery. 
1.5 Stroke and Neural stem cells 
The hope that neural stem cells can play a role in recovery from stroke has been 
investigated in earnest for the past two decades. This was accelerated when it was 
discovered that NPCs are able to respond to an ischemic injury and migrate to the site of 
injury (A. Arvidsson, Collin, Kirik, Kokaia, & Lindvall, 2002; Parent et al., 2002). The 
ability of NPCs to give rise to the three major cell types in the brain; neurons, astrocytes 
and oligodendrocytes, increases the hope that these cells can help aid in stroke recovery 
(Gage, Ray, & Fisher, 1995; Kornblum, 2007). The question remains: if NPCs migrate to 
the site of injury and can differentiate into mature cells, why is there no tissue 
regeneration or repair of the injury site and a lack of full functional recovery? 
NPCs respond to an ischemic injury by proliferating and migrating to the site of injury, 
but these NPCs do not integrate into the post-ischemic cortex. The majority of these 
NPCs do not become mature neurons (Kokaia, Thored, Arvidsson, & Lindvall, 2006; 
Osman et al., 2011; Parent et al., 2002). Therefore the question remained what is the fate 
of these NPCs?  To assess if neuroblasts, a subtype of NPCs, which migrate to the site of 
injury play a role in stroke recovery, a knock-out model for neuroblasts was produced. 
Doublecortin (Dcx) positive neuroblasts were selectively knocked out by transfection of 
herpes simplex virus thymidine kinase and thereby, became sensitive to the anti-viral 
drug ganciclovir. Knocking out neuroblasts caused an increase in the infarct size and 
significantly greater sensorimotor deficits post-stroke (Jin, Wang, Xie, Mao, & 
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Greenberg, 2010). This demonstrated that neuroblasts have a role in promoting stroke 
recovery, although they do not become mature neurons. NPCs have the ability to provide 
trophic support through the secretion of growth and survival factors to the surrounding 
cells (MacLellan et al., 2011; Tsai et al., 2006). Therefore, by remaining in an 
undifferentiated state, neuroblasts may provide trophic factor support to cells surrounding 
the infarct (Tsai et al., 2006). Further studies exploring when NPCs respond to ischemic 
injuries and how they minimize the size of injury may potentially identify novel 
treatments post-stroke. 
Unfortunately, the majority of NPCs and specifically neuroblasts do not survive upon 
migrating to the infarct. These neuroblasts die through apoptosis (Thored et al., 2006). 
Blocking apoptosis has been shown to increase their numbers in the post-ischemic cortex 
(Osman et al., 2011). If apoptosis can be specifically inhibited within neuroblasts, then 
identifying their role in the post-ischemic cortex and methods to promote their neural 
differentiation may be found. One method to improve the survival of NPCs post-stroke is 
overexpressing the anti-apoptotic protein, Bcl-xL which blocks apoptotic cell death 
(Doeppner et al., 2010). Improving NPC survival may allow differentiation into mature 
cell types in the post-ischemic cortex and/or the survival of the surrounding cells through 
trophic support. Improving the survival of NPCs in the post-ischemic cortex and 
specifically blocking apoptosis in NPCs may lead to a viable therapy post-stroke. 
Minimizing the size of ischemic injuries and how neuroblasts respond to an ischemic 
injury are currently being studied. Previous studies on the time course of the neuroblast 
response and migration towards the site of injury have been confined to a resolution of 
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weeks (A. Arvidsson et al., 2002; Parent et al., 2002). As part of the NPC response post-
stroke, an increase in migratory neuroblasts in the ischemic cortex peaked by 1 week 
post-stroke and continued to be elevated up to 16 weeks post-stroke (Kokaia et al., 2006). 
To characterize the acute phase post-stroke, this study examined the cellular response to 
stroke over the first 10 days when the NPC response is at its peak. This examination may 
potentially lead to identifying an optimal time point of the NPC response that can then be 
exploited for interventional therapies. 
The response of NPCs and the hope to improve functional recovery post-stroke has been 
studied in earnest over the past decades with many different approaches being used to 
understand and exploit NPCs. This has led to many different avenues into using NPCs 
post-stroke including increasing endogenous precursor survival and exogenous 
implantation of hydrogels with NPCs (Lagace, 2012). Unfortunately, there remains a 
need to uncover the optimal time window post-stroke where there is a peak response from 
the neural precursor population. 
1.6 Models of ischemic stroke in rodents 
To understand ischemic stroke and to test novel therapies there must be clinically relevant 
laboratory models of ischemic stroke. Animal models of stroke, especially rodent models, 
have become the standard in testing novel therapies for stroke recovery. Each model of 
stroke has its own specific strengths and weaknesses and no model, however well-
planned, will be able to perfectly mimic human stroke (Carmichael, 2005). Therefore 
each model will have specific advantages and disadvantages. 
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1.6.1 Criteria 
All models need to have the hallmarks of the disease they are modeling; therefore there 
are universal criteria that must be addressed for clinical validity. The majority of rodent 
stroke models use rats, but more studies are adapting rat models for use with mice to take 
advantage of transgenic strains (Clarkson et al., 2013; Horie et al., 2008; Osman et al., 
2011; Roome et al., 2014; Tennant & Brown, 2013).  A number of characteristics of 
human stroke that should be modeled in experimental stroke models include: the size of 
ischemic injuries and reperfusion of the brain after stroke. The first characteristic is the 
size of the stroke. When the injury comprises over 145 cm3 in size, or over 30% of cortex 
it is defined as a malignant stroke in humans (Carmichael, 2005; Wartenberg, 2012). 
These strokes are extremely debilitating and are associated with low survival and poor 
stroke recovery. While it would be ground-breaking to be able to reverse the low survival 
of these larger strokes, currently the greatest gains can be made by treating and improving 
the recovery of smaller strokes. Therefore, the goal is to model smaller strokes in which 
outcomes are more favourable and have the greatest potential to be responsive to novel 
therapies. The second characteristic is reperfusion following ischemic stroke. 
Spontaneous reperfusion occurs in 20% of ischemic strokes (Olsen & Lassen, 1984). The 
introduction of clot busting agents are increasing the rate of reperfusion (Carmichael, 
2005). Stroke models that allow for reperfusion are needed to model the current state of 
stroke. In this study, a small focal stroke in which reperfusion occurs was used.  
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1.6.2 Endothelin-1 induced ischemia 
A focal model of ischemia and the one that will be used in this thesis is intracortical 
injections of Endothelin-1 (ET-1). ET-1 is a vasoactive peptide and when injected 
intracortically will lead to a lack of blood flow due to constriction of the blood vessels 
surrounding the injection site (Adkins-Muir & Jones, 2003; Fuxe et al., 1997; Hughes et 
al., 2003). After the injection, ET-1 is metabolized and reperfusion is established 
(Macrae, Robinson, Graham, Reid, & McCulloch, 1993). ET-1 acts on two receptors in 
endothelial cells lining the blood vessels: endothelin receptor A and endothelin receptor 
B. Endothelin receptor A has a vasoconstrictive effect on endothelial cells and endothelin 
receptor B has a vasodilative response (Horie et al., 2008). One challenge for using ET-1 
as a model of focal ischemia in mice is that expression of the vasodilative endothelin 
receptor B is twice as high as the vasoconstrictive endothelin receptor A (Wiley & 
Davenport, 2004). This receptor profile is different from that of rats, leading mice to be 
less sensitive to ET-1 induced ischemic injury. However, Dr. Vanderluit's lab has 
recently developed a model of ischemic injury in the mouse using multiple intra-cortical 
injections of high concentrations of ET-1 to create a reproducible infarct in the mouse 
forelimb motor cortex (Roome et al., 2014). With the new model of ET-1 injections, there 
are more opportunities to use ET-1 as a model of ischemic stroke in mice. 
The use of ET-1 injections as a model of ischemic stroke has grown in popularity in rats 
because of its ability to create localized infarcts (Carmichael, 2005). An advantage of the 
ET-1 injection model is that is it possible to target infarcts to a specific location to cause 
either a mostly gray matter injury such as in this study or an injury targeting the white 
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matter. The MCAo model causes extensive damage to both gray and white matter and is 
not useful for studying the impact of infarcts that are localized to the gray matter. This is 
important for translation studies where gray matter injuries have been shown to be at a 
higher risk of permanent damage in human strokes. Stroke models that exclusively target 
the gray matter therefore are important to understanding these injuries (Falcao et al., 
2004).  Infarcts caused by ET-1 injections into rodents are well defined and reproducible 
based upon a strong correlation between ET-1 dosage and infarct volume(Fuxe et al., 
1997). ET-1 injuryies show evidence of infarction in the area surrounding the ET-1 
injection site where damage has been confirmed using cresyl violet and fluoro Jade-B 
staining (Macrae et al., 1993; Tsenov, Mátéffyová, Mareš, Otáhal, & Kubová, 2007). As 
modern techniques become available and refined, more aspects of human stroke in 
rodents are able to be accurately modeled. Although no model of ischemic stroke will 
ever be able to truly mimic human stroke the use of in vivo models is crucial to the 
improvement of stroke recovery. 
1.7 Rationale 
Despite numerous studies focused on endogenous NPCs post-stroke, there is a lack of 
successful therapies arising from these studies (Gladstone et al., 2002). One of the major 
hurdles in harnessing the neurogenic abilities of NPCs is that the vast majority of NPCs 
undergo apoptosis and die prior to contributing to the recovery post-stroke (A. Arvidsson 
et al., 2002; Osman et al., 2011). However, new studies have shown that some cells are 
able to survive and mature into functional interneurons in the striatum (Hou et al., 2008). 
This leads to the promise that NPCs may be able to improve stroke.  To optimize the use 
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of NPCs as a therapy, there must be improved survival of NPCs post-stroke. To increase 
the survival of NPCs, identifying the optimal time window in which to manipulate the 
largest number of NPCs needs to be identified to have the greatest possible impact on 
recovery post-stroke. Additionally, glial cells can play a role in supporting NPCs post-
stroke and control the size of the infarct (Sabelström et al., 2013). Therefore this thesis 
focuses on assessing and characterizing the glial response to stroke. This is in addition to 
analyzing the proliferation of NPCs following a small focal ischemic injury. 
Understanding when glial cells and NPCs respond to a focal ischemic injury can help 
identify the optimal window to improve NPC survival post-stroke.   
 
1.7.1 Research Goal: 
The characterization of a small ischemic injury and the responses of glia and NPCs in the 
hope of identifying an optimum time period for interventional therapies. 
1.7.2 Aims:  
To address the research goal this thesis has two aims: 
1. Characterize infarct progression and the glial response following a small focal 
ischemic injury. 
2. Characterize the response of NPCs, specifically newly born neuroblasts over the 
first 10 days post-ischemic injury. 
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2 Methods and Materials: 
2.1  Mice 
Adult male FVBN mice were singly housed on a 12hr light/dark cycle. Mice had access 
to water and standard rodent chow ad libitum. All experiments were approved by the 
Memorial University institutional animal care committee in accordance with the 
guidelines from the Canadian Council on Animal Care. 
2.2 Surgery 
2.2.1 Endothelin-1 surgery 
Mice were anesthetized using isoflurane (Aerrane, 02225875, Baxter, Ontario, Canada) 
and placed into the stereotaxic instrument (308019R, David Kopf Instruments, California, 
United States). Mice were kept warm with a heating pad throughout the surgery. Lanalin 
was placed on the eyes to prevent drying. 50µL of buprenorphine was injected into the 
rump. The fur covering the top of the skull was removed using a razor. An incision was 
made in the scalp in an anterior to posterior direction allowing access to the skull. The 
periosteum was scraped away using a cotton tipped applicator. Lambda and Bregma 
sutures were marked using an ultra fine tipped marker. Injection co-ordinates were 
marked onto the skull. An Ideal Microdrill (67-1000, Cellpoint Scientific, Maryland, 
United States) was used to drill into the skull. The meninges were then scraped away 
allowing access to the cortex. Either Endothelin-1 or 0.9% NaCl solution was loaded into 
the pulled glass needle (TW 100F-4, World Precision Instruments, Sarasota, Florida, 
United States). Injections were performed at three co-ordinates relative to Bregma: (i) 1.5 
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anterior/posterior (A/P) and 0.7 medial/lateral (M/L); (ii) 1.75 A/P and 0.4 M/L; and (iii) 
1.25A/P and 0.1M/L. Each injection was performed at two depths, with 0.5µL being 
injected at a depth of 0.8mm from the top of the cortex, and a further 0.5µL being 
injected at a depth of 1.2mm from the surface of the cortex. The injections were 
performed at a rate of 0.1µL/minute and were controlled using a syringe pump (Fusion 
100, Chemyx, Texas, United States), with a 5 minute hold after infusion to prevent back 
flow. This was repeated for each of the three injection sites. After injections, the needle 
was removed and three steel sutures were used to pull the skin over the initial incision. 
2mL of lactated ringer’s solution was given subcutaneously on the rump to prevent 
dehydration during recovery. The mouse was placed into a cage with food available on 
the floor as well as being heated on one side for 1-3 hours to prevent hypothermia. 
2.3 Tissue collection 
2.3.1  Labeling of proliferating cells 
To label actively dividing cells on the day of collection, mice were given 4 intraperitoneal 
injections of bromodeoxyuridine (BrdU, 100µg/g body weight, B5552, Sigma, Ontario, 
Canada) in two hour intervals. Mice were euthanized 30 minutes following the last BrdU 
injection. 
2.3.2 Perfusion and cryosectioning 
Prior to perfusion, the mouse was given a 300µL overdose of sodium pentobarbital. 
Transcardial perfusion was performed once the mouse was unresponsive. The chest 
cavity was opened to expose the heart. Once accessible, the right atrium was cut to allow 
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for blood drainage, and 10mL of chilled phosphate buffered saline pH 7.4 (PBS) was 
injected into the left ventricle. Subsequently, 20mL of chilled 4% paraformaldehyde pH 
7.4 (PFA) was injected through the left ventricle to fix the tissue. Following perfusion 
brains were dissected and postfixed overnight in 4% PFA. Brains were subsequently 
cryoprotected using sucrose solution in PBS, changed daily, from 12% (w/v) to 16% 
(w/v) and 16% (w/v) to 22% (w/v). Brains were frozen in O.C.T. TissueTek mounting 
medium (25608-930, Sakura Finetek, California, United States) using 2-methylbutane. 
Brains were cryosectioned (Microm HM520, Thermo Scientific, Ontario, Canada) into 
14µm thick coronal sections. Tissue was collected on slides (Superfrost Plus, 12-550-15, 
Fisher, Ontario, Canada) throughout the A/P extent of the injury. 
2.4 Histological staining 
2.4.1  Cresyl violet staining 
Sections spaced 140µm were selected for cresyl violet staining. Slides were placed on a 
slide warmer at 37oC for 30 minutes prior to being stained in 0.1% cresyl violet solution 
(C1791, Sigma, Ontario, Canada) for 45 minutes. Slides were then dehydrated in a series 
of ethanol/water solutions, (50%(v/v), 70%(v/v), 90%(v/v), 95%(v/v),  and 100% (v/v) 
times 3), followed by isopropanol and toluene prior to coverslipping using Permount 
(SP15-500, Fisher, Ontario, Canada). 
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2.4.2  Immunohistochemistry: 
2.4.2.1  Fluorescent immunohistochemistry 
Three slides were chosen for fluorescent immunohistochemistry (IHC), which previously 
were identified to be representative of the 1mm A/P range of the centre of the infarct by 
cresyl violet staining. Slides were placed on a slide warmer at 37oC for 20 minutes and a 
hydrophobic moat was drawn around the tissue to retain antibody solution (Dako Pen, 
S200230-2, Dako, Ontario, Canada). For BrdU IHC, slides were post-fixed in acetone for 
2 minutes, and subsequently treated with 2N hydrochloric acid for 30 minutes at 37oC to 
allow nuclear penetration of the antibody, followed by 0.1M sodium borate (pH 8.0) for 
10 minutes for neutralization. Subsequently slides were washed in PBS for 20 minutes 
and incubated overnight with the proper primary antibody (Table 2.1). The following 
morning slides were washed in PBS for 20 minutes and incubated with the corresponding 
secondary antibody (Table 2.2) for 1 hour. After incubation slides were washed in PBS 
for 10 minutes, and counterstained with Hoechst (1:250, BisBenzimide H33258, B1155, 
Sigma, Ontario, Canada) for 2 minutes, and washed in PBS for 10 minutes. Slides were 
then coverslipped using 125µL of a 1:3 glycerol:PBS solution.  
28 
 
Table 2.2.1 Primary Antibodies 
Specificity Host Concentration Source 
BrdU Mouse 1:100 BD Biosciences 347580 
Doublecortin Goat 1:200 Santa Cruz sc-8066 
GFAP Goat 1:400 Santa Cruz sc-6171 
CD-68 Rat 1:400 ABD Serotec MCA1957 
Active Caspase 3 Rabbit 1:400 BD Biosciences 559565 
 
Table 2.2.2 Fluorescent Secondary Antibodies 
Specificity Fluorphore Concentration Source 
Mouse Alexa Fluor 594 1:200 Invitrogen A21203 
Goat Alexa Fluor 488 1:200 Invitrogen A11055 
Rabbit Alexa Fluor 488 1:200 Invitrogen A21206 
 
2.4.2.2 Immunohistochemistry using enzymatic detection 
IHC with enzymatic detection was performed as follows; slides were warmed on a slide 
warmer for 20 minutes. Slides were then washed in a 100mM Tris HCl pH 7.5 0.15M 
NaCl solution (Tris buffer) for 20 minutes and a hydrophobic moat was drawn around the 
tissue to retain antibody solution (Dako Pen, S200230-2, Dako, Ontario, Canada). The 
slides were incubated in primary antibody overnight (Table 2.1). The following 
mornings, slides were washed in Tris buffer for 20 minutes, followed by an endogenous 
peroxidase treatment of 0.3% hydrogen peroxide in methanol. Slides were then washed in 
Tris buffer for 20 minutes. Following washing the slides were incubated with the 
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appropriate secondary antibody (Table 2.3). For biotinylated conjugated secondary 
antibodies, an avidin biotin complex (VECTASTAIN Elite ABC kit (Universal), PK-
6200, Vector Laboratories, Ontario, Canada) kit was used to amplify the enzymatic 
detection. The slides were then washed in Tris buffer for 20 minutes. Slides were then 
incubated in DAB solution (DAB Peroxidase Substrate Kit, 3,3’-diaminobenzidine, SK-
4100, Vector Laboratories, Ontario, Canada) for 5 minutes, until suitable staining 
developed, then washed in tap water for 5 minutes. Slides were then dehydrated in 
ethanol as detailed in section 2.4.1 and coverslipped in Permount mounting media (SP15-
500, Fisher, Ontario, Canada). 
Table 2.2.3 DAB Secondary Antibodies 
Specificity Detection 
Enzyme 
Concentration Source 
Rabbit Biotinylated 1:200 Jackson 11-065-152 
Rat HRP 1:200 Jackson 112-035-008 
 
2.5 Infarct Volume and Edema Factor analysis 
Infarct volume was assessed by imaging cresyl violet slides. Slides were photographed 
using a Zeiss Axiocam Mrm camera, through a Zeiss stereoscope (Stemi-2000 C, Carl 
Zeiss Microscopy, Jenna, Germany). Infarct volume was determined by measuring the 
outline of the infarct on coronal sections at 140µm intervals through the A/P extent of the 
injury. To achieve this, the area of the cortex contralateral to the injury was compared to 
the area of healthy cortex on the hemisphere ipsilateral to the injury. Volume was 
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estimated by integrating the changes in area over the 140µm distance between 
representative sections, using the equation below:  
               
                                                                         
The infarct volume was corrected for edema. The edema factor was calculated in 
accordance with literature and multiplied by the infarct volume (Belayev et al., 2005). 
             
                               
                                 
 
 The corrected infarct volume can then be calculated using the following equation: 
                        
           
                                                              
            
  
2.6 Immune cell area of activation 
The area of immune cell activation was measured using ImageJ (NIH, 
http://rsbweb.nih.gov/ij/) and two sections spanning the centre of the injury. 
Photomicrographs were taken using a Zeiss Axiocam Mrm camera, at 3.2X magnification 
on a Zeiss stereoscope (Stemi-2000 C, Carl Zeiss Microscopy, Jenna, Germany). 
Activated immune cells were traced and averaged over the two sections per animal. 
2.7 Cell counting 
Cell counts were performed using ImageJ (NIH, http://rsbweb.nih.gov/ij/). Nine sections 
from 3 slides, spanning a 1mm area that spanned the centre of the infarct previously 
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identified by cresyl violet staining, were selected per mouse for immunohistochemical 
staining. Photomicrographs were taken using a Zeiss Axiocam Mrm camera at 20X 
magnification on a Zeiss Imager.Z1 microscope (Zeiss Imager.Z1, Carl Zeiss 
Microscopy, Jenna Germany). Slides were blinded prior to quantification. Quantification 
of NPCs within the subventricular zone (SVZ) was completed by quantifying BrdU 
positive cells along the entire length of the SVZ of the ventricle ipsilateral to the infarct. 
Quantification of double labelled BrdU and Dcx positively labelled neuroblasts was 
completed by ensuring co-localization of BrdU and Hoechst in Dcx positive cells along 
the entire length of the SVZ of the ventricle ipsilateral to the infarct. 
2.8 Densitometry analysis 
Densitometry was performed using ImageJ software (NIH, Massachusetts, United States). 
All images were blocked into 62500µm2 areas. Consecutive representative sections 140 
µm apart were used from the centre of the infarcted area as assessed by cresyl violet 
staining. Rodbard correction (NIH, http://rsbweb.nih.gov/ij/) was used to standardize gray 
levels for analysis. Five gridded sections were used to measure gray levels within the 
region of interest. Three areas of interest were used on non-stained gray matter as 
background control levels. The density of the areas of interest were averaged and then 
subtracted with the average of the background areas. To assess astrocyte activation, areas 
were selected along the border of the injury as determined by the lack immunostaining 
within the injury, and areas at a distance of 250µm lateral to the border of injury. 
32 
 
2.9 Statistical testing 
GraphPad Prism 5 (GraphPad Sofware, California, United States) was used to perform all 
statistical tests. The Student’s t-test was used to compare experimental and control 
conditions of neuroblast survival, with p-value for significance set at 0.05. One-way and 
two-way Analysis of Variance (ANOVA) tests were used with the Bonferroni post-hoc 
test to compare the statistical significance between time points for neural precursor 
population quantification and newborn neuroblast quantification, α-value for significance 
was set at 0.05.
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3 Results 
The Vanderluit lab has recently developed a model of ischemic stroke that involves 
intracortical injections of ET-1 into the mouse forelimb motor cortex (Roome et al., 
2014). The goal of this research project was to use this stroke modelto study the 
progression of the infarct over the first 10 days post-stroke. This included analysis of the 
volume of the infarct, the cell death profile, and the glial and NPC responses. To 
specifically understand the NPC response post-stroke, both NPC proliferation and 
newborn neuroblast levels were assessed. The goal of this strategy was to characterize the 
acute cellular changes occurring within and surrounding the infarct.  
3.1  The infarct volume is consistent over the first 10 days post-injury 
To test if the volume of an ischemic injury changed over the first 10 days post-injury, 
cresyl violet staining was used to differentiate healthy tissue from injured tissue. Cresyl 
violet stained the endoplasmic reticulum of cells dark purple (Fig. 3.1). When tissue 
became injured, cells shrunk and the distance between cells increased, this led to areas of 
pale cresyl violet staining. High magnification of the border between injured and healthy 
tissue showed the differences between healthy cells and condensed injured cells (Fig. 3.1 
A). Areas with small shrunken cells, indicated by white arrows, were judged to be 
damaged and included in the injury (Fig. 3.1 A). Areas where cells were mainly healthy, 
indicated by the black arrows, with few dead cells were considered to be not injured (Fig. 
3.1 A). Measurements of injured tissue showed sizable injuries in both saline and ET-1 
conditions (Fig. 3.1 B-E). Ischemic injuries have a distinctive shape, with injuries flaring 
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out at the bottom of the cortex (Fig. 3.1 B-E). Saline injuries have a different shape than 
ischemic injures, with saline injuries being shallower and bowl shaped (Fig. 3.1 B-E). 
Saline injuries also appear to have fewer pale areas (Fig. 3.1 B-E). Statistical analysis of 
injury volumes showed that ET-1 induced infarcts were only significantly larger than 
saline injuries at 7 days post-surgery but not at the other time points (Fig. 3.1 F). 
Although infarct volumes between ET-1 and saline injuries were not significantly 
different at all time points; statistical analysis revealed main effects for time. A trend 
towards smaller infarct volumes for both ET-1 and saline injuries appeared at 10 days 
versus earlier time points.  The edema factor for both ET-1 and saline injuries did not 
change significantly over time post-surgery, remaining stable at a mean of 1.15 across the 
time points (Fig. 3.1 G). Although not significant, a trend towards smaller injuries was 
observed in both ET-1 and saline injuries between the 1st day and the 10th day post-
surgery. 
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Figure 3.1: Infarct volume is stable following initial injury. 
A - Representative high magnification (10X) photomicrographs of cresyl violet staining 
near the border of the injury. Line indicates the border of the injury. Black arrows 
indicate healthy cells while white arrows indicate small shrunken cells. 
B-E - Representative photomicrographs (2.5X) of cresyl violet staining of coronal 
sections through the cortex of saline and ET-1 injuries at 1 (B), 3 (C), 7 (D) and 10 (E) 
days post-surgery. Injury areas are traced in black. 
F - Quantification of injury volume at 1, 3, 7 and 10 days post-surgery. Data is 
represented as means plus or minus standard error of the mean (± SEM). Means were 
analyzed by two-way ANOVA revealing significant effects for treatment [F(1,23)=13.43, 
p=0.0013], and time [F(3,23)=3.358, p=0.0363] then followed by Bonferroni posthoc 
tests. (1d, n=4 saline, n=4 ET-1; 3d, n=4 saline, n=3 ET-1; 7d, n=4 saline, n=3 ET-1; 10d, 
n=4 saline, n=5 ET-1). *p<0.05. Edema factor was measured for each injury.  
G - Quantification of edema factor at 1, 3, 7 and 10 days post-surgery. Data is represented 
as mean ± SEM. Means were analyzed by two-way ANOVA revealing no significant 
effects. Dotted line at 1.00 represents the baseline of no edema. 
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3.2 Apoptotic cell death occurs up to 3 days post-stroke 
To understand how the infarct is formed and the ongoing changes within the post-
ischemic cortex, the cellular death response between ischemic and saline injuries was 
examined. To determine whether apoptotic cell death occurred post-stroke, 
immunohistochemistry for active caspase 3 was performed. Active caspase 3 is a 
hallmark of apoptotic cell death. Apoptosis was confirmed using Hoechst, a nuclear cell 
stain, to visualize condensed apoptotic nuclei. Extensive apoptotic cell death was not 
observed in either ET-1 or saline injuries. Immunostaining did reveal a few apoptotic 
cells surrounding the ET-1 induced infarct at 1 and 3 days post-stroke (Fig. 3.2 B,F). Due 
to the low level of apoptotic cell death, quantification was not performed. Apoptosis 
appeared to occur in small clusters at 1 day post-stroke. By 3 days post-stroke, fewer 
apoptotic cells were observed. No apoptotic cell death was detected by 
immunohistochemistry for active caspase 3 at 7 and 10 days post-stroke (data not shown). 
Apoptotic cells were not detected in saline injuries at any time point. Although no active 
caspase 3 positive cells were observed in saline injuries (Fig. 3.2 A,E), high 
magnification photomicrographs revealed shrunken but not apoptotic nuclei at both 1 and 
3 days post-surgery (Fig. 3.2 C,G). This suggests a specific window for apoptosis up to 3 
days post-stroke, and it occurs in ischemic injuries but not saline injuries. 
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Figure 3.2: Apoptotic cell death is seen up to 3 days post-injury. 
Immunohistochemical staining for active caspase 3 was performed to label cells 
undergoing apoptosis. Hoechst, a nuclear stain, was used to confirm apoptotic nuclei. 
Representative photomicrographs of immunohistochemical staining for active caspase 3 
and Hoechst were taken from saline and ET-1 induced injures at 1 and 3 days post-injury. 
A,B- Active caspase 3 (AC3) staining at 1 day post-surgery revealed no active caspase 3 
staining in saline injuries. However in ET-1 conditions small groups of positively labeled 
cells can be observed. High magnification (20X) of active caspase 3 positive cells with 
arrows indicating apoptotic cells (inset). 
C,D- Hoechst staining at 1 day post-surgery. The apoptotic nuclear morphology is not 
observed in cells within saline injuries. In contrast, condensed, apoptotic nuclei are 
observed in ET-1 injuries. High magnification (20X) of cell nuclei (insets). 
E,F- Similarly, at 3 days post-surgery, active caspase 3 positive cells were not observed 
in saline injuries, whereas, a few active caspase 3 positive cells were observed in ET-1 
injuries. High magnification (20X) of AC3 positive cells in the ET-1 injury with an arrow 
indicating the apoptotic cell (inset). 
G,H- Hoechst staining at 3 days post-surgery. The apoptotic nuclear morphology is not 
observed in cells within saline injuries cells, however, condensed apoptotic nuclei are 
observed in ET-1 injuries. High magnification (20X) of nuclei (insets).  An arrow 
indicates an apoptotic cell (inset).   
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3.3 Astrocytes are activated surrounding the injury post-stroke 
3.3.1 The morphology of astrocytes changes post-ischemic injury. 
Immunohistochemistry for GFAP, a marker for astrocytes, was used to compare the 
morphology of astrocytes in naïve, saline and ischemic brains at 7 days post-injury. Gray 
matter astrocytes appear to have upregulated GFAP and have larger, swollen cell bodies 
in both ET-1 and saline brains compared to naïve controls (Fig. 3.3). Additionally, 
activated astrocytes appear to have more processes than non-activated astrocytes (Fig. 
3.3). White matter astrocytes appear to be aligned along the tracts of white matter (Fig. 
3.3). These hallmark characteristics including swollen cell bodies, increased number of 
processes and upregulated GFAP expression were used to differentiate activated from 
non-activated astrocytes. 
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Figure 3.3: Morphological changes associated with astrocyte activation post-stroke. 
Representative photomicrographs of GFAP immunohistochemical staining of naïve, 
saline and ET-1 treated brains at 7 days post-surgery. Activated astrocytes residing in 
gray matter appear to have an increased number of processes in both ischemic and saline 
conditions. Activated astrocytes residing in white matter appear swollen compared to 
naïve conditions in both saline and ET-1 conditions. In ET-1 conditions distinct processes 
can be seen in white matter astrocytes. Arrows indicate increased processes on activated 
astrocytes. 
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3.3.2 Activation of astrocytes spreads across the ischemic cortex. 
Glial scars play a sizable role in shaping the post-ischemic cortex by forming a barrier to 
contain ROS and extracellular glutamate and by secreting pro-survival factors (Deb et al., 
2010). Therefore, understanding when and how astrocytes respond to a focal ischemic 
injury can potentially be used to provide an optimal target window for interventional 
therapies. Immunohistochemistry for GFAP, revealed activated astrocytes in both ET-1 
and saline injuries (Fig. 3.3). When all time points are viewed there appears to be a 
progression of astrocyte activation across time in both saline and ET-1 injured brains. At 
1 day post-surgery, there is some astrocyte activation surrounding the sites of injury (Fig 
3.4A,B). By 3 days post-surgery, activated astrocytes can be seen outside the site of 
injury and there appears to be a lack of GFAP immunostaining within the injury (Fig 
3.4C,D). By 7 days post-surgery, activated astrocytes appear to have spread across the 
ipsilateral hemisphere in both saline and ET-1 injured brains (Fig 3.4E,F). In ET-1 
injured brains, astrocyte activation was also observed in the contralateral hemisphere 
(Fig. 3.4F). By 10 days post-surgery, GFAP immunostaining appears reduced in saline 
treated brains whereas intense GFAP immunostaining is still observed in the ipsilateral 
hemisphere in ET-1 injured brains (Fig. 3.4G,H). However, astrocyte activation is no 
longer observed in the contralateral hemisphere in ET-1 injured brains at this time point. 
This decrease in astrocyte activation at 10 days post-surgery may suggest a possible start 
of the resolution of astrocyte activation.  
By 7 days post-surgery, astrocyte activation appears to have spread across the ischemic 
cortex into the contralateral cortex (Fig. 3.4F, 3.5B). At the same time point in saline 
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treated brains, activated astrocytes were seen near the ischemic injury, but few activated 
astrocytes were seen in the contralateral cortex (Fig. 3.5A). This is in contrast to ET-1 
treated brains, where numerous activated astrocytes are observed in the contralateral 
cortex in 3 out of 4 animals examined (Fig.3.5B). This characterization of astrocyte 
activation shows that astrocytes may respond differently to a saline-mediated injury 
versus an ischemic injury. 
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Figure 3.4: Ischemia induces widespread astrocyte activation in the injured cortex. 
Representative photomicrographs of brain sections showing immunohistochemical 
staining for GFAP, which is upregulated during astrocyte activation in saline and 
ischemic injuries at 1, 3, 7 and 10 days post-injury. 
A,B- At 1 day post-injury saline and ET-1 induced injuries show GFAP staining at the 
site of injury and along the border of the injury. 
C,D- At 3 days post-injury saline and ET-1 injuries show GFAP staining at the border of 
the injury but minimal staining in the core of the injury. 
E,F- At 7 days post-injury saline injuries show GFAP staining at the border and in the 
ipsilateral cortex to the injury. However, at 7 days post-injury in the ET-1 condition 
robust GFAP staining can be seen in the contralateral cortex in addition to staining 
throughout the ipsilateral cortex. Arrow indicates GFAP staining in the contralateral 
cortex. 
G,H- At 10 days post-injury saline induced injuries show GFAP staining primarily at the 
site of injury. In ET-1 induced injuries GFAP staining is observed throughout the 
ipsilateral cortex but no longer is GFAP staining observed within the contralateral cortex.   
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Figure 3.5: Activation of astrocytes in the contralateral cortex at 7 days post-
surgery. 
Representative photomicrographs of coronal brain sections showing 
immunohistochemical staining for GFAP, which is upregulated by activated astrocytes. 
A- Representative low magnification (1.25X) of a brain section from a saline induced 
injury. A` shows high magnification (20X) of the ipsilateral cortex where activated 
astrocytes are observed. A`` shows high magnification of the contralateral cortex and 
shows no significant GFAP staining. 
B- Representative low magnification (1.25X) of a brain section from a ET-1 induced 
injury. B` high magnification (20X) of the ipsilateral cortex, where numerous activated 
astrocytes are observed. B`` high magnification of the contralateral cortex, where 
activated astrocytes are observed. 
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3.3.3 Densitometry of GFAP shows ischemic injuries have a greater spread of 
astrocyte activation than saline injuries. 
To assess astrocyte activation surrounding saline and ET-1 injuries, densitometry of 
GFAP immunostaining was performed in two areas, at the border of the ischemic injury 
and 250µm from the injury border (Fig. 3.6 A). GFAP densitometry showed no 
significant difference between levels of activation surrounding the site of injury between 
ET-1 and saline injuries (Fig. 3.6 B). Statistical analysis of astrocyte activation 250 µm 
from the border of the injury revealed main effects for treatment and interaction. 
Specifically at 7 days post-surgery, there was higher GFAP upregulation 250 µm from 
the border of the injury in ET-1 injuries compared to saline injuries (Fig 3.6 C). Therefore 
while saline injuries do cause astrocyte activation surrounding the injury at similar levels 
to ET-1 mediated injuries, the activation further from the site of injury is stronger in ET-1 
mediated injuries at 7 days post-surgery. 
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Figure 3.6: Densitometry shows the spread of astrocyte activation across the injured 
cortex. 
A- Densitometry of GFAP staining was performed on representative 
photomicrographs of brain sections at 1, 3, 7 and 10 days post-injury. Red boxes show 
areas of measurement along the border of the ischemic injury and green boxes show areas 
of densitometry measured 250µm from the border of the injury. 
B- Quantification of GFAP densitometry, at the border of the injury (red boxes). 
Means were analyzed by two-way ANOVA revealing no significant effects. 
C- Quantification of GFAP densitometry from areas 250µm from the border of the 
injury (green boxes). Means were analyzed by two-way ANOVA revealing main effects 
for treatment [F(1,24)=4.640, p=0.0415] and interaction [F(3,24)=3.059, p=0.0476] then 
followed by Bonferroni posthoc tests. (1d, n=4 saline, n=4 ET-1; 3d, n=4 saline, n=3 ET-
1; 7d, n=4 saline, n=4 ET-1; 10d, n=4 saline, n=5 ET-1). *p<0.05 
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3.4 Immune cells are activated within the injury over the first 10 days 
post-stroke 
Along with activated astrocytes, the immune system is part of the glial response to stroke. 
Understanding when and where immune cells are activated post-stroke allows for testing 
the role of the immune system in modulating the NPC response. To examine the immune 
response, immunohistochemistry was performed to detect activated microglia and 
macrophages. Specifically, antibodies to CD-68, a cell surface marker of activated 
microglia and macrophages, were used (Slepko & Levi, 1996). Brain sections were 
selected from the centre of the injury. A few CD-68 positive cells were observed within 
the infarct at 1 day post-surgery as shown in insets in saline and ET-1 treated brains (Fig 
3.7 A,B). By 3 days post-surgery however, robust expression of CD-68 was observed in 
both saline and ET-1 treated brains (Fig. 3.7 C,D). In contrast to the location of astrocyte 
activation, CD-68 immunostaining was confined to the site of injury. The spread of CD-
68 immunostaining appeared restricted to the core of the injury at 7 and 10 days post-
surgery in both saline and ET-1 injured brains (Fig. 3.7 E-H). Cells that were activated by 
10 days post-injury were localized to the area surrounding the centre of the infarct (Fig. 
3.7 G,H).  
Although robust immune cell activation was first observed 3 days post-stroke, the 
expression of CD-68 positive cells was wide spread across the injury. To assess changes 
in the spread of CD-68 positive cells within the injury across time post-surgery, the area 
of CD-68 immunopositive cells was analyzed. At 3 and 7 days post-surgery, there was a 
significantly larger area of CD-68 positive cells in ET-1 injured brains compared to saline 
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injured brains (Fig. 3.8 A). By 10 days post-surgery, the area of CD-68 activation was 
reduced and no longer significantly different from saline treated brains (Fig. 3.8 A).  
Next, densitometry of CD-68 was performed to assess the levels of microglia and 
macrophage activation within the injury. No significant differences were found between 
groups across the different time point post-surgery (Fig. 3.8B). Densitometry was not 
performed at 1 day post-surgery because CD-68 immunostaining was below detection 
levels in both ET-1 and saline treated brains. Overall our results suggest that the immune 
response to an ET-1 induced injury peaks at day 3-7 post-surgery, then subsides by day 
10 to levels similar to that of the saline group. The areas of activated immune cells, when 
compared to the infarct area, were similar to the corresponding infarct areas. 
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Figure 3.7: Ischemic injury causes a robust innate immune response. 
Representative photomicrographs of brain sections showing immunohistochemical 
staining for CD-68, a marker for activated microglia and macrophages, in saline and 
ischemic injuries at 1, 3, 7 and 10 days post-injury. Areas of activated immune cells are 
outlined in black. 
A,B- At 1 day post-injury few CD-68 positive cells were observed located proximal to 
the needle tract (inset) in both saline and ET-1 conditions.  
C,D- At 3 days post-injury robust activation of microglia and macrophages was first 
detected at 3 days post-injury in both saline and ET-1 induced injuries. 
E,F-  Robust CD-68 staining continued at 7 days post-injury in both saline and ET-1 
induced injuries.  
G,H- At 10 days post-injury CD-68 staining is found in close proximity to the needle 
tract in both saline and ET-1 induced injuries. 
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Figure 3.8: Microglia and macrophages have a larger response to ischemic injuries 
than saline over the first 10 days post-injury. 
A- The area of CD-68 activation was measured on representative photomicrographs 
of brain sections at 3, 7 and 10 days post-surgery. Red outline shows the area of CD-68 
activated cells. Means were analyzed by two-way ANOVA revealing significant main 
effects of treatment [F(1,18)=28.02, p<0.0001], time [F(2,18)=6.972, p=0.0057] and 
interaction [F(2,18)=6.362, p=0.0081] then followed by Bonferroni posthoc tests. 
*p<0.05, ***p<0.001. 
B- Densitometry of CD-68 was performed on representative photomicrographs of 
brain sections at 3, 7 and 10 days post-injury. Red boxes show areas for density 
measurements within the injury. Means were analyzed by two-way ANOVA and showed 
no significant effects. (1d, n=4 saline, n=4 ET-1; 3d, n=4 saline, n=3 ET-1; 7d, n=4 
saline, n=4 ET-1; 10d, n=4 saline, n=5 ET-1). 
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3.5 Neural precursor cell proliferation changes over the first 10 days 
post-stroke 
To study the impact of a small focal ischemic injury on the proliferative status of NPCs, 
BrdU was used as a marker for proliferating cells in the SVZ. BrdU is a thymidine analog 
that is taken up by cells during the S-phase of the cell cycle. BrdU injections labeled the 
proliferative population of the SVZ for 6 hours prior to sacrifice. Statistical analysis of 
NPC proliferation within the SVZ ipsilateral to the injury did not reveal any significant 
differences between saline and ET-1 treatments over the first 10 days post-injury (Fig 3.9 
B). 
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Figure 3.9: NPCs proliferate within the SVZ over the first 10 days post-surgery. 
A- Representative photomicrographs of sections from saline and ET-1 treated brains 
showing BrdU labeled cells within the SVZ at 1, 3, 7 and 10 days post-surgery. The 
choroid plexus resides within the lateral ventricle fluoresces due to nonspecific staining. 
B- Quantification of the total number of BrdU positive SVZ cells over a 1120 µm 
A/P distance through the centre of the infarct. Data is presented as mean ± SEM. Dotted 
line represents basal proliferation levels in naïve age-matched controls. Error bars at the 
one day time point for ET-1 conditions are not visible due to the low variance seen at that 
time point (SEM=4124.658). Means were analyzed by two-way ANOVA and revealed a 
significant main effect for time, due to the surgical procedure [F(3,24)=3.019, p=0.0495]. 
(1d, n=4 saline, n=4 ET-1; 3d, n=4 saline, n=3 ET-1; 7d, n=4 saline, n=4 ET-1; 10d, n=4 
saline, n=5 ET-1; n=3 naïve). 
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3.6 Newborn migratory neuroblasts are selectively increased at 7 days 
post-stroke 
One of the most well studied subpopulations of NPCs post-stroke is the neuroblast 
population. Neuroblasts migrate away from the SVZ towards the site of injury (A. 
Arvidsson et al., 2002). To assess if there was a change in the number of newborn 
neuroblasts, immunohistochemistry was performed for doublecortin (Dcx), a marker for 
migratory neuroblasts and BrdU (Gleeson, Peter T, Flanagan, & Walsh, 1999). Cells 
double positive for Dcx and BrdU were considered the newborn neuroblast population 
and quantified within the SVZ (Fig.3.10 A). Statistical analysis of the mean estimated 
number of newborn neuroblasts revealed significantly higher numbers in ET-1 treated 
brains (363,626.7) versus saline treated brains (208,320.0) at 7 day post-surgery (Fig. 
3.10 B). An overall increase in only Dcx positive cells was also observed in both saline 
and ET-1 treated brains (Fig. 3.10 A). These cells are not actively proliferating within the 
SVZ and have the potential to migrate towards the site of injury. Although attempted, 
quantification of Dcx positive cells appeared unreliable due to the high expression of 
doublecortin in cell processes and difficulty clearly identifying individual cells bodies. 
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Figure 3.10: Significant increase in the number of newborn neuroblasts 7 days after 
ischemic injury. 
A-  Representative photomicrographs of brain sections showing BrdU and Dcx 
double labeled cells (arrows) in the SVZ of naïve, saline and ET-1 treated brains 7 days 
post-surgery.  
B- Quantification of the number of newborn neuroblasts shows a significant increase 
in numbers within the SVZ in ET-1 treated brains at 7 days post-stroke. Data is presented 
as mean ± SEM. Dotted line represents basal newborn neuroblast levels from naïve age-
matched controls (n=3). Means were analyzed by two-way ANOVA revealing significant 
effects of treatment [F(1,23)=5.324, p=0.0304], time [F(3,23)=7.614, p=0.0010] and 
interaction [F(3,23)=4.827, p=0.0095] then followed by Bonferroni posthoc tests. (1d, 
n=4 saline, n=4 ET-1; 3d, n=4 saline, n=3 ET-1; 7d, n=4 saline, n=3 ET-1; 10d, n=4 
saline, n=5 ET-1). **p<0.01 
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4 Discussion 
4.1 Major findings in this thesis 
This thesis has followed the endogenous responses of the mouse brain to a small focal 
ischemic injury. This has included the characterization of glial and NPC responses over 
the first 10 days post-stroke. The major findings from this thesis include the stability of 
the injury size over that time. Another major finding was the progression of astrocyte 
activation across the injured hemisphere following both ET-1 and saline injections. 
However, astrocyte activation in the contralateral cortex was primarily observed 
following an ischemic injury. Immune cell activation was delayed, however, by three 
days a robust response was observed within the injury site. This is depicted by the spread 
of activated astrocytes in black and immune cells in red in figure 4.1. In contrast to the 
characterization of the glial cell responses, the overall proliferative NPC response did not 
change over the first 10 days post-surgery. However, a significant increase in the 
newborn neuroblast population, a subset of the NPC population, occurred at 7 days post-
stroke. This is demonstrated by the increase in the green cells in figure 4.1. Taken 
together, the findings in this thesis have identified and characterized the endogenous 
cellular responses to a new model of small focal ischemic injuries.  
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Figure 4.1: Endogenous responses to a small focal ischemic injury. 
Cartoon representation of the progression of the endogenous cellular responses to a small 
focal ischemic injury over the first 10 days post-stroke. The spread of astrocyte activation 
is specifically shown across the ischemic cortex, which was observed at 7 days post-
stroke. The delayed immune response is demonstrated with the activated immune cells 
being confined within the core of the injury. Additionally, the newborn neuroblast peak 
levels across the first 10 days was observed at day 7 post-surgery. Together, this depicts a 
highly dynamic situation over a large area of the brain from a small focal ischemic injury. 
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4.1.1 Minor fluctuations in ET-1 ischemic injury size over the first 10 days 
post-stroke. 
The size of the injury was relatively stable across the first 10 days post-stroke. However, 
a significant increase in infarct volume was observed at 7 days post-stroke which was 
reduced by 10 days post-stroke. One of the limitations of this study was the low sample 
sizes of 3-5 animals per time point. This low sample size could lead to increased 
variance. Although there was no overall change in the size of the infarct between the first 
day and tenth day post-stroke, an overall trend towards smaller injury volumes were 
observed. These minor changes in injury volumes across the first 10 days post-stroke are 
consistent with focal size of the injury and small amount of accompanying edema. This 
contrasts with other models of ischemic injury. The MCAo model creates a much larger 
infarct that results in greater edema. Over the first week post-stroke edema resolves and 
the injury shrinks (Kuraoka, Furuta, Matsuwaki, & Omatsu, 2009). This shrinkage in 
MCAo injuries causes a change in corrected infarct volume from 20% to 10% between 1 
day and 8 days post-stroke (Kuraoka et al., 2009; Lehrmann, Christensen, Zimmer, 
Diemer, & Finsen, 1997). Therefore, edema following MCAo injuries is a main 
contributing factor for changes in injury volume. In contrast in this study following an 
ET-1 mediated stroke, the level of edema was small, with an average edema factor of 
1.15, resulting in minimal impact on infarct volume. In human stroke, the primary cause 
of death in large malignant strokes is inflammation of the brain, a large component of the 
inflammation is edema which comprises over 30% of the infarct volume (Kasner et al., 
2001). Although there are strong similarities with the level of edema between MCAo 
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injuries and malignant strokes, the high mortality with malignant strokes suggest little 
can be done. In contrast, the smaller injury size of the ET-1 model is more consistent with 
focal strokes in humans in which treatment strategies are possible. The ET-1 model 
therefore, may have more clinical relevance to test therapeutic treatments. 
In this ET-1 mediated model of ischemic injury, there was very little delayed apoptotic 
cell death. This is uncharacteristic compared to other models of focal ischemia, where 
cell death is mostly necrotic at the time of insult, followed by a secondary cell death 
phase that is mostly apoptotic (Sairanen, Karjalainen-Lindsberg, Paetau, Ijäs, & 
Lindsberg, 2006). Necrotic cell death was not assessed in this study, and an examination 
of apoptotic cell death revealed some active caspase 3 staining at 1 day post-stroke which 
declined by 3 days post-stroke.  Apoptotic cell death was no longer observed at 7 and 10 
days post-stroke. This was in contrast to the saline injuries where no active caspase 3 
labeling was observed, only a few apoptotic nuclei. Apoptotic cell death following 
ischemia is associated with the delayed excitotoxic response to excess extracellular 
glutamate which occurs between 0-24 hours post ischemia (Dávalos, Castillo, Serena, & 
Noya, 1997). The apoptotic process takes approximately 6-24 hours (Saraste & Pulkki, 
2000) and since apoptotic cells are positive for active caspase-3 for a period of 
approximately 4 hours, it is highly likely that some apoptotic cells were missed between 1 
and 3 days post ischemia.  
Although the results show a trend towards smaller injury volumes from 1 to 10 days post-
stroke, significant cell death was not observed beyond 3 days suggesting that changes in 
injury volume cannot be attributed to apoptotic cell death. Thus, the lack of apoptosis at 7 
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and 10 days post-stroke and the low level of edema following a small ET-1 injury results 
in a relatively stable sized injury within one week post-stroke. This is in contrast to the 
larger changes in the stroke volume observed in larger injuries such as MCAo.  
4.1.2 Glial cell activation is spatially and temporally defined by different cell 
types. 
In this study, the responses of glial cells were assessed to both ET-1 injections and saline 
injections. Activated astrocytes were observed in both ET-1 and saline conditions, 
however a greater level of activated astrocytes were observed further from the site of 
injury in ET-1 conditions. While studying the immune cell response to both ET-1 and 
saline injuries, robust activated immune responses were not observed until 3 days post-
injury. When activated immune cells were observed, they were confined to the site of 
injury and any separation of resident microglia and infiltrating macrophages was not 
possible using the immunohistochemical markers available. However when the two types 
of injuries were compared a greater area of activated immune cells was observed in ET-1 
mediated injuries. The differences in the quality of the glial cells responses between ET-1 
and saline injuries are further proof to the validity of the ET-1 injection model of focal 
ischemia. 
4.1.2.1 Astrocyte activation spreads across the cortex. 
Following an ET-1 stroke, astrocyte activation spreads across the injured cortex. This has 
been characterized over the first 10 days through the following observations. Immediately 
following a stroke, astrocytes become activated surrounding the injury. By 3 days post-
stroke, astrocyte activation has spread across the ipsilateral cortex and by 7 days it has 
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spread into the contralateral cortex. While the upregulation of GFAP expression as an 
indicator of astrocyte activation did not differ between cells that were at the border of the 
injury, the presence of activated cells further from the site of injury was significantly 
greater by 7 days post-stroke. Astrocytes are commonly activated following ischemic 
injuries (Gladstone et al., 2002). In MCAo injuries, astrocytes are activated as early as 4 
hours post-stroke and begin to decrease by 14 days post-stroke (Barreto et al., 2012; 
Sofroniew, 2009; Stoll, 1998). Despite a decrease in the levels of astrocyte activation 
over time, astrocytes surrounding the injury site remain activated in larger models of 
ischemic injury (Sofroniew, 2009; Stoll, 1998). Following MCAo, astrocyte activation as 
assessed by GFAP upregulation is seen throughout the ipsilateral cortex beginning at 4 
hours post-stroke, continuing until 7 days post-stroke, and persisting around the border of 
the injury up to 60 days post-stroke (Nowicka, Rogozinska, Aleksy, Witte, & Skangiel-
Kramska, 2008). Robust levels of astrocyte activation were also found in the peri-infarct 
area in photothrombosis (Kuraoka et al., 2009; Nowicka et al., 2008). This persistent 
activation of astrocytes was observed in this study along the border of the injury as 
demonstrated at 10 days post ET-1 induced stroke. Astrocytes remain activated near the 
border of the injury. Until the current study, the spread of astrocyte activation into the 
contralateral cortex has not previously been reported. Although an ET-1 ischemic infarct 
is significantly smaller than an MCAo or photothrombotic infarct, we observed extensive 
activation of astrocytes across the ipsilateral cortex and into the contralateral cortex. To 
the best of my knowledge, the spreading of astrocyte activation was observed for the first 
time in this thesis. As this study only examined the first 10 days post-stroke, it is unclear 
the duration of astrocyte activation or whether it would be comparable in a human stroke 
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brain. One potential mechanism to mediate the spread of astrocyte activation is cell to cell 
communication through gap junctions (Huang et al., 2012). Further studies into 
identifying the mechanism that mediates the spread of astrocyte activation and what role 
it plays in the contralateral cortex is important to understand the full impact these cells 
can have in stroke recovery.  
The contrasting roles of activated astrocytes, having both pro and anti-inflammatory 
effects, give them a complex role in the post-stroke cortex. Activated astrocytes play a 
pro-survival role by secreting factors that aid neuronal survival. These factors include 
adenosine triphosphate (ATP), glutamate and D-serine in quantities that can promote cell 
survival in a controlled manner (Deb et al., 2010; Guthrie et al., 1999). This is in addition 
to neurotrophic factors like BDNF, NGF and heat shock proteins (Hsps) (do Carmo 
Cunha et al., 2007; White, Yin, & Jakeman, 2008). Post-stroke there is a large 
uncontrolled release of glutamate from dead and dying cells (Brassai, Suvanjeiev, Bán, & 
Lakatos, 2015). One of the pro-survival functions of astrocytes post-stroke, is the ability 
to uptake this potentially cytotoxic glutamate (Sofroniew, 2009; Takatsuru et al., 2013). 
However, astrocytes also produce ROS, which can induce apoptosis, and result in the 
release of excess glutamate (Deb et al., 2010; Sofroniew, 2009; Stoll, 1998). If glutamate 
is released in high concentrations, it is excitotoxic to neurons. Astrocytes play a 
protective role by uptaking excess toxic glutamate and metabolizing it into the non-toxic 
neurotransmitter precursor glutamine (Takatsuru et al., 2013). Astrocytes therefore, have 
a direct impact on the survival of surrounding cells. Therefore, it is important to 
understand where and when astrocytes are activated in the cortex post-stroke. In the 
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future, strategies may be able to target their activation to promote the survival of cells 
post-stroke. 
4.1.2.2 Microglia and macrophages show a delayed reaction to an ischemic 
injury. 
Following either a saline or ET-1 injection, activated immune cells, as demonstrated by 
α-CD-68 immunohistochemistry were first observed at 3 days post-surgery in this study. 
Few to no cells were observed at 1 day, except along the needle tract. Although the 2 day 
time point was not assessed, by 3 days post-surgery widespread CD-68 positive cells 
were observed throughout the injury sites. By 10 days post-stroke, the number of 
activated immune cells had decreased with cells centered once again around the needle 
tracts. A larger area of α-CD-68 positive cells was found following an ET-1 injury 
consistent with larger injury volumes in stroke injuries versus saline injuries. However, 
no significant differences were detected in the density of activated immune cells within 
the injuries at any time point. While the area covered by activated immune cells does 
change over the first 10 days post-stroke, the level of activation, as measured by the 
amount of CD-68 did not change. Furthermore the level of CD-68 upregulation can be 
attributed to the damage caused by the injury because both saline and ET-1 induced 
injuries resulted in a similar level of CD-68 upregulation. One of the potential reasons for 
the area of activated immune cells remaining elevated by 7 days post-surgery can be a  
breakdown of the blood brain barrier which would allow infiltrating macrophages to enter 
the injury (Brouns & De Deyn, 2009). However, it is not uncommon for activated 
immune cells to be detected from as early as 6 hours through to 21 days following MCAo 
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(Lehrmann et al., 1997; Nowicka et al., 2008; Walberer et al., 2010). This suggests that 
larger injuries may recruit more peripheral macrophages. It is important to note that while 
immune cell activation following MCAo and photothrombosis is larger than what is seen 
in ET-1 mediated ischemic injuries, immune cell activation is confined to the infarct core 
in all ischemic models (Lehrmann et al., 1997; Nowicka et al., 2008; Taylor & Sansing, 
2013). Post-mortem studies in human tissue have reported immune cell activation early at 
24 hours post-stroke and higher levels at 72 hours post-stroke through the use of Iba-1 
and radiolabeling for activated microglia (Price et al., 2006; Taylor & Sansing, 2013). 
These findings are in contrast to my results where little to no immune cell activation was 
observed at 1 day post-stroke with anti-CD-68 immunohistochemistry. Although not 
examined in this study, assessing immune cell activation at 2 days following an ET-1 
stroke may have demonstrated when cells are activated following injury. However, 
extensive immune cell activation was observed within the injury site by 3 days post-
surgery consistent with other stroke models. The reduction in the area occupied by 
activated immune cells by 10 days post-stroke, suggests that the immune response is 
beginning to resolve. In contrast, current models of focal ischemia, such as MCAo create 
larger injuries that recruit a large immune response which often don't become quiescent 
up to 60 days post-stroke (Nowicka et al., 2008). Therefore, the significantly smaller 
injury observed in an ET-1 meditated ischemic injury creates a smaller immune response 
than that observed following MCAo. Small injuries in which the immune cell activation 
become resolved faster than in large injuries will be valuable to assess the progression of 
the immune response post-stroke and its importance in promoting neural repair.  
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4.1.3 The newborn neuroblast cells are significantly increased within the SVZ 
over the 10 days post-stroke. 
Following either saline or ET-1 injections, no significant change in cell proliferation was 
observed within the SVZ over the first 10 days post-stroke. This is in contrast to the 
proliferative response seen in MCAo and photothrombosis models of ischemic injury. In 
these models there is a significant increase in the proliferating population from 1 week up 
to one year post-stroke (Osman et al., 2011; Thored et al., 2006).  Previous studies have 
shown that the size of an injury is positively correlated with the proliferative response 
from NPCs (Thored et al., 2006). In this study, while there was robust positive staining 
there was no significant change seen between ischemic conditions and saline controls. 
Therefore, the proliferative response from a small focal ischemic injury, such as the one 
in this study, may be too small to be detected using the current BrdU labeling protocol. 
Other potential explanations for the lack of detection of a NPC response in this study may 
be attributed to the characteristics of BrdU and the protocol employed in this study. BrdU 
only labels cells during S-phase of the cell cycle and has a half-life in vivo of 2 hours. In 
this study, mice received IP injections on the day of euthanasia every 2 hours over a 6.5hr 
period, therefore only cells in S-phase during this 6.5 hour window would be labeled with 
BrdU. The goal of the labeling protocol used in the study was to identify the time point 
following stroke when NPCs within the SVZ respond by increasing proliferation. 
Proliferating NPCs were only quantified in the ipsilateral hemisphere and comparisons 
were made between ET-1 and saline injected brains. Due to the small size of the ET-1 
induced infarct and the damage associated with a saline injection there were no 
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significant differences in the number of proliferating cells. Although comparisons were 
not made between ET-1, saline and naïve any differences in proliferation above that of 
naïve would be attributed to the damage associated with the cortical injections. 
Different markers of cell proliferation may provide a different picture. For instance, Ki67 
is a protein that is upregulated during all phases of the cell cycle (Abeysinghe, Bokhari, 
Dusting, & Roulston, 2014). Ki67 immunohistochemistry therefore labels all cells that 
are proliferating at the time of sacrifice. In contrast, BrdU labels cells in S-phase of the 
cell cycle. Therefore the trade-off is labeling all proliferating cells at a specific time 
point, or identifying the cells that are actively dividing over a two hour time period. 
Alternatively BrdU can be applied over a longer time course, to capture a larger 
proportion of the proliferative population (Arvidsson et al., 2002). Although this would 
capture more global changes in the proliferative state of cells, it lacks the precision of the 
shorter time window. The lack of precision is because it is impossible to determine when 
the cell was labeled during a given BrdU pulse, only that the cell had undergone mitosis 
during the pulse. This is one of the reasons why this study has a focal approach to BrdU 
administration that occurs during one period, therefore all BrdU positive cells had 
undergone mitosis on the day of sacrifice. 
One goal of understanding the NPC response post-stroke is to selectively study 
neuroblasts, the NPC population that responds to a stroke by differentiating. This thesis 
shows there is a significant increase in the newborn neuroblast population  that responds 
to a small focal ischemic injury, and peaks at 7 days post-stroke. This subset of the NPC 
population can leave the SVZ and migrate towards the site of injury (Doetsch, 2003; 
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Ohab, Fleming, Blesch, & Carmichael, 2006).  The peak of the newborn neuroblast 
response corresponds to similar time points in other models, such as MCAo and 
photothrombosis, where the maximum number of migrating neuroblasts are observed at 1 
and 2 weeks post stroke (Osman et al., 2011; Thored et al., 2006). However, these models 
show a more robust response than observed in the current ET-1 mediated small focal 
injury, likely because larger injuries induce a larger NPC response (Abeysinghe et al., 
2014). Unfortunately, few studies assess the NPC response within the first week post-
stroke (A. Arvidsson et al., 2002; Osman et al., 2011; Parent et al., 2002; Thored et al., 
2006). There is a lack of knowledge of how soon the NPC response is initiated post-
stroke. In the current study, the NPC response was examined at 1, 3, 7 and 10 days post-
stroke. We found an increase in newborn neuroblasts at 7 days which was diminished 3 
days later. There are a few possible reasons for the decrease observed. One is that the 
increase is a transient response and by 10 days post-stroke these neuroblasts may have 
differentiated into mature cell types or do not survive. Additionally, NPCs could have 
migrated from the SVZ either along the rostral migratory stream or into the cortex while 
quantification was confined to the SVZ. Another question is why there was a response in 
the newborn neuroblasts with no significant increase in the NPC population observed. A 
possible explanation is that the change in the newborn neuroblast population is not large 
enough to significantly affect the levels of the total proliferative population of the SVZ. 
This could occur because the majority of the proliferative population remains in a state of 
self-proliferation as opposed to differentiation into neuroblasts (Thored et al., 2006). In 
conclusion, this thesis has shown that the total NPC population does not change its 
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proliferative state at any specific time point over the first 10 days post-stroke, but it does 
have an increase of the newborn neuroblast population at 7 days. 
4.2 Future Directions 
This thesis focused on the characterization of a small focal ischemic injury and has led to 
a number of interesting questions. These questions can be classified into two groups. The 
first focuses on the glial responses post-stroke, and the second involves understanding the 
NPC responses in the hope to improve their survival post-stroke. The focus on the glial 
responses includes identifying the mechanism of the spread seen in astrocyte activation 
and the role astrocytes play in the cortex outside of the peri-infarct area post-stroke. This 
is in conjunction with assessing the immune response to an ischemic injury. This includes 
how immune cells infiltrate and when breakdown of the blood brain barrier occurs in this 
model of ischemic injury. The second group of questions, focusing on the NPC 
responses, would be trying to target the differentiating population of NPCs post-stroke, 
when this differentiation occurs and how the migratory neuroblasts can be targeted to 
improve their survival in the ischemic cortex. Overall, these future directions can build 
upon the findings in this thesis in the hope of improving stroke recovery. 
The first direction is to follow the glial cell responses post-stroke. Specifically, the first 
experiment would be identifying the potential mechanism behind the spread of astrocyte 
activation across the ischemic cortex and into the contralateral hemisphere post-stroke. 
Another potential experiment would be to assess the role of gap junctions in activating 
astrocytes post-stroke. Gap junctions have the ability to directly mediate communications 
between cells by forming physical connections between the cells. There has been research 
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into the role gap junctions play in mediating neuroprotection post-stroke, and the subunits 
that compose gap junctions (Kozoriz et al., 2010). Specifically assessing the role of gap 
junctions in affecting the spread of astrocyte activation may be observed through the 
transfer of a gap junction permeable dye such as calcein-AM. This method would assess 
the activity of gap junctions as a method to transport potential signalling molecules 
between astrocytes (Roemer, Lammerich, Conroy, & Weisensee, 2013). If gap junctions 
are the source of the spread of astrocyte activation post-stroke, then modifying gap 
junctions could confine where astrocytes are activated post-stroke.  
The second part of the glial response studied was the immune cell response to a small 
focal ischemic injury. Future directions from this study include understanding why there 
is a delay in the response of the immune cells to an injury. Is this delay consistent with a 
breakdown of the BBB, and when does this breakdown occur? Breakdown of the BBB 
allows macrophages to infiltrate into the brain (Kawano et al., 2012; Walberer et al., 
2010). This could lead to selectively studying the response of microglia as the only 
immune cells responding to an injury prior to the breakdown of the BBB. Additionally, 
the role that these immune cells play in the brain can be further investigated by assessing 
immune cell polarization as either cytotoxic M1 or neurotrophic M2 phenotypes 
(Benarroch, 2013; Taylor & Sansing, 2013). If there is a switch between M1 and M2 
phenotypes, determining when this switch occurs and if there is a method to promote the 
M2 phenotype could provide a therapy to promote recovery post-stroke.  
The second group of future directions involves studying the NPC responses post-stroke. 
In this thesis, there has been a specific increase in the newborn neuroblast response at 7 
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days post-stroke. The goal of tracking neuroblasts from the SVZ towards the site of injury 
and determining their fate once they arrive is still very much a possibility with different 
techniques. Techniques such as labelling NPCs through viral transfection or 
electroporation would allow for more robust tracking. If robust tracking is possible then 
targeting these NPCs with genetic based therapies would allow for temporal control of 
novel therapies in vivo. One method to improve tracking, and then introduce genetic 
therapies into NPCs is through in vivo electroporation or virus infection of a plasmid 
containing a fluorescent reporter or a potentially therapeutic gene. Introducing a pro-
survival gene via these methods could produce new mature neurons into the injured brain 
and potentially improve stroke recovery. If these NPCs, including differentiating 
neuroblasts, can migrate to the site of injury and survive they can play two major roles in 
promoting repair (Burns & Steinberg, 2011). The first is their ability to differentiate into 
mature neurons that can help replace some of the lost neurons. The second major role 
these NPCs can play is to provide support to the surviving cells at the site of injury (Ohab 
et al., 2006). It is important to be able to leverage their abilities to become mature 
functioning neurons in the brain post-stroke. 
4.3 Conclusion 
This thesis has characterized the endogenous responses following a small focal ischemic 
injury. This has included identifying a stable sized injury following ET-1 mediated 
ischemic injury, with apoptotic cell death up to 3 days post-stroke. The responses of glial 
cells were studied with both activated astrocytes and immune cells being quantified up to 
10 days post-stroke. This showed for the first time a spread of astrocyte activation into 
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the contralateral cortex to the ischemic injury. This is an exciting observation that shows 
how astrocytes play a larger role across areas that have previously been assumed to be 
healthy and minimally affected by a small ischemic injury. Additionally, the NPC and 
newborn neuroblast populations were quantified over the first 10 days post-stroke and a 
peak level of newborn neuroblasts was identified at 7 days post-ischemic injury. This can 
potentially be used as a target for impacting the highest number of newborn neuroblasts 
to improve survival and have an impact on stroke recovery.
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